Avanir Pharmaceuticals, Inc. (AVNR)
-NasdaqGS 3.41 
0.01(0.29%) 4:00PM EDT|After Hours
:
3.40 0.01 (0.29%) 5:00PM EDT
| Prev Close: | 3.40 |
|---|
| Open: | 3.37 |
|---|
| Bid: | 3.35 x 400 |
|---|
| Ask: | 3.43 x 100 |
|---|
| 1y Target Est: | 7.33 |
|---|
| Beta: | 1.48 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 3.32 - 3.43 |
|---|
| 52wk Range: | 2.07 - 4.05 |
|---|
| Volume: | 1,105,857 |
|---|
| Avg Vol (3m): | 1,221,510 |
|---|
| Market Cap: | 494.82M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.40 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Avanir Pharmaceuticals to Participate in Two Upcoming Investor ConferencesPR Newswire(Wed, May 22)
- July Options Now Available For Avanir Pharmaceuticals (AVNR)at TheStreet(Mon, May 20)
- AVANIR PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Investors Ride 5 Healthcare Earnings Rollercoaster Ridesat Wall St. Cheat Sheet(Sun, May 12)
- Avanir Pharmaceuticals Increases Sales but Misses Estimates on Earningsat Motley Fool(Fri, May 10)
- Avanir Reports Strong Revenue but Misses on Earningsat Motley Fool(Thu, May 9)
- Wider-than-Expected Loss at AvanirZacks(Thu, May 9)
- AVANIR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Avanir Pharmaceuticals' CEO Discusses F2Q13 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- Avanir Pharmaceuticals Earnings: Here’s Why Investors Don’t Like These Resultsat Wall St. Cheat Sheet(Wed, May 8)
- Avanir Pharmaceuticals Earnings Call scheduled for 4:30 pm ET todayCCBN(Wed, May 8)
- Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business ResultsPR Newswire(Wed, May 8)
- AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Wed, May 8)
- Q2 2013 Avanir Pharmaceuticals Earnings Release - After Market CloseCCBN(Wed, May 8)
- Generic Drug Pricing Pressure Remains in Western Europe, While Central and Eastern Europe, Latin America and Parts of Asia Eye Fairly Strong Growth in Generic DrugsWall Street Transcript(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 8.50 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Sep-13)
: | -0.37 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.09 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | -0.16 |
|---|
Business Summary
Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States.
View More